Home

EDV
EDV
EDV
Covid EDV Vax Booster
We need healthy heroes to volunteer for our vaccine trial against COVID 19

We are looking for volunteers who:
• are 18 years and older
• are in good health
• have been vaccinated or recovered from COVID-19 at least 4 months prior
• or have never received a vaccine

For more information, please contact our Clinical Trials Team

For more information
MORE INFO
EDVs
The EDV nanocell is a first-in-class cyto-immunotherapy platform targeting the tumor directly and leveraging the patient’s own immune system.
Careers
Currently Recruiting
READ MORE
previous arrowprevious arrow
next arrownext arrow
Shadow

 

Breaking News

 

Australian Biotech EnGeneIC Strikes Landmark Deal with Major US Bio-tech ImmunityBio for COVID-19 Vaccine and Cancer Treatment

EnGeneIC develops world-first nanocellular anti-COVID-19 vaccine that defeats mutant viruses and stimulates a broad anti-viral response

Click for full story

Works against mutant strains including Delta & Omicron. No need for refrigeration during transport and storage. No added stabilisers or chemicals. Safety and immune response clinical trial recruiting now in Melbourne, Sydney & Perth to follow. Efficacy trial planned for USA.

For more information about becoming a volunteer for the COVID-19 EDV™ Vaccine Trial contact our Clinical Trials Team.

Learn more about EnGeneIC Dream Vector (EDV™) Nanocell platform technology

Publication in prestigious scientific journal, Cancer Cell, highlighting the ability of EDV™ Nanocells to mount dual assault on Cancer Cells

EDV™ Technology Stimulates Both Innate and Adaptive Immune Response and Confers Long-Term Survival

Abstract accepted  to the Annual Meeting of the American Society of Clinical Oncology 2020

Abstract Demonstrates Promising Early Results from Phase I/IIa study in Patients with Recurrent, Metastatic Pancreatic Cancer.